Press Release September 9, 2003

21st Century Solutions Designed To Meet 21st Century Challenges

Anti-depressant, Proton Pump Inhibitor Lead First-Half 2003 Promotion to Key Managed Care Executives, Cognet-X Inc. Reports

FEASTERVILLE---(September 9, 2003)-Forest Laboratories Inc.'s Lexapro and TAP Pharmaceuticals Inc.'s Prevacid were the prescription drugs most heavily promoted to managed care pharmacy directors during the first 6 months of 2003, Cognet-X Inc. data show.

Lexapro, the newer of Forest Laboratories two anti-depressants, also emerged as the most promoted brand during the second quarter, according to Cognet-X's PAR-Rx (Promotional Assessment Research) Report™. The PAR-Rx Report tracks pharmaceutical company promotion to pharmacy directors at the most influential managed care organizations and pharmacy benefit management companies in the country.

In addition, second-quarter PAR-Rx data show that TAP's Prevacid generated more contacts to PAR-Rx panelists than did any product other than Lexapro. Prevacid also held the second-place spot during the first quarter of the year.

Strattera, Eli Lilly & Co.'s Attention Deficit/Hyperactivity Disorder (ADHD) product, which launched in the first quarter, placed third in terms of total first-half promotion. Strattera generated only one contact less than Prevacid and three less than Lexapro.

In fourth place during the first half of 2003 was Aventis Pharmaceuticals' non-sedating antihistamine, Allegra, followed by Lilly's new osteoporosis injectable, Forteo, in fifth position. Allegra promotion spiked upward in the second quarter, generating more contacts to PAR-Rx panelists than any products besides Lexapro and Prevacid.

Allegra's rival, Schering-Plough Corp.'s Clarinex, was one of two products to finish the second quarter in fourth place; GlaxoSmithKline's new antidiabetic agent, Avandamet tied with Allegra as the fourth most promoted brand.

Four products tied to be the fifth most promoted brand, according to the PAR-Report: Astelin from MedPointe Inc., Cardizem LA from BioVail Pharmaceuticals, Emend from Merck & Co. Inc. and Wyeth's Protonix.

About the PAR-Rx Report

Cognet-X's PAR-Rx Report is a year-round service that provides the pharmaceutical industry with real-time, Internet-based competitive intelligence on pharmaceutical company promotion to influential managed care pharmacy directors.

The Report offers Cognet-X clients the ability to evaluate and analyze variable differences that are critically important to their decision-making process. The Report collects comprehensive data that can be segmented and analyzed to provide clients with "21st-Century solutions to their 21st-Century challenges."

About Cognet-X

Cognet-X offers the pharmaceutical industry market research, consulting and software development that help companies build and refine their relationships with numerous customer bases, including the managed care community. Based in Bucks County, Pennsylvania, Cognet-X is privately held and employee-owned.

For more information on the PAR-Rx Report or other valuable Cognet-X products, please contact James A. Barone at (215) 396-8300 (extension 102) or Rick Bourland (extension 103) or via e-mail at jimb@cognetx.com or rickb@cognetx.com.

Home | Feedback | Up

Cognet-X Inc.
1210 NorthBrook Drive, Suite 150
Feasterville, PA 19053
Toll Free: 1-866-cognetx (264-6389)
Or
E-mail us at
info@cognetx.com
sales@cognetx.com